These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 9504062

  • 1. Empirical antifungal therapy in febrile neutropenic patients: current status.
    Kibbler CC.
    Curr Top Med Mycol; 1997 Dec; 8(1-2):5-14. PubMed ID: 9504062
    [Abstract] [Full Text] [Related]

  • 2. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhédin N, Isnard F, Ades L, Kuhnowski F, Foulet F, Kuentz M, Maison P, Bretagne S, Schwarzinger M.
    Clin Infect Dis; 2009 Apr 15; 48(8):1042-51. PubMed ID: 19281327
    [Abstract] [Full Text] [Related]

  • 3. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.
    Bennett JE, Powers J, Walsh T, Viscoli C, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Kauffman C, Lee J, Pappas P, Rex J, Verweij P.
    Clin Infect Dis; 2003 Apr 15; 36(Suppl 3):S117-22. PubMed ID: 12679895
    [Abstract] [Full Text] [Related]

  • 4. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis.
    Karthaus M, Hentrich M.
    Mycoses; 2011 Jan 15; 54 Suppl 1():1-6. PubMed ID: 21126265
    [Abstract] [Full Text] [Related]

  • 5. Empiric antifungal therapy in patients with febrile neutropenia.
    Ferrara JJ, MacDougall C, Gallagher JC.
    Pharmacotherapy; 2011 Apr 15; 31(4):369-85. PubMed ID: 21449626
    [Abstract] [Full Text] [Related]

  • 6. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J.
    Clin Infect Dis; 2005 Nov 01; 41(9):1242-50. PubMed ID: 16206097
    [Abstract] [Full Text] [Related]

  • 7. Febrile neutropenia in haematological malignancies.
    Sharma A, Lokeshwar N.
    J Postgrad Med; 2005 Nov 01; 51 Suppl 1():S42-8. PubMed ID: 16519255
    [Abstract] [Full Text] [Related]

  • 8. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.
    Sugar AM.
    Arch Intern Med; 1990 Nov 01; 150(11):2258-64. PubMed ID: 2241435
    [Abstract] [Full Text] [Related]

  • 9. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I, Sanz MA.
    Enferm Infecc Microbiol Clin; 1999 Nov 01; 17 Suppl 2():95-102. PubMed ID: 10605194
    [Abstract] [Full Text] [Related]

  • 10. Prevention and treatment of invasive fungal diseases in neutropenic patients.
    Almyroudis NG, Segal BH.
    Curr Opin Infect Dis; 2009 Aug 01; 22(4):385-93. PubMed ID: 19506476
    [Abstract] [Full Text] [Related]

  • 11. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer.
    Lin MT, Lu HC, Chen WL.
    Clin Infect Dis; 2001 Nov 15; 33(10):1621-7. PubMed ID: 11595977
    [Abstract] [Full Text] [Related]

  • 12. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D, Buadi FK, McClune B.
    Pharmacotherapy; 2008 Jan 15; 28(1):58-63. PubMed ID: 18154475
    [Abstract] [Full Text] [Related]

  • 13. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J.
    J Antimicrob Chemother; 2009 May 15; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [Abstract] [Full Text] [Related]

  • 14. Empirical antifungal therapy.
    Klastersky J.
    Int J Antimicrob Agents; 2004 Feb 15; 23(2):105-12. PubMed ID: 15013034
    [Abstract] [Full Text] [Related]

  • 15. Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients.
    Rieger CT, Ostermann H.
    Mycoses; 2008 Feb 15; 51 Suppl 1():31-4. PubMed ID: 18471159
    [Abstract] [Full Text] [Related]

  • 16. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S.
    Cancer; 2002 Jun 15; 94(12):3230-46. PubMed ID: 12115356
    [Abstract] [Full Text] [Related]

  • 17. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century.
    Sipsas NV, Bodey GP, Kontoyiannis DP.
    Cancer; 2005 Mar 15; 103(6):1103-13. PubMed ID: 15666328
    [Abstract] [Full Text] [Related]

  • 18. [Antimicrobial prophylaxis and therapy in neutropenia].
    Link H.
    Mycoses; 2003 Mar 15; 46 Suppl 2():21-32. PubMed ID: 15055140
    [Abstract] [Full Text] [Related]

  • 19. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, Wingard JR.
    Clin Infect Dis; 2007 Feb 01; 44(3):402-9. PubMed ID: 17205448
    [Abstract] [Full Text] [Related]

  • 20. Empirical antifungal therapy in treating febrile neutropenic patients.
    Wingard JR.
    Clin Infect Dis; 2004 Jul 15; 39 Suppl 1():S38-43. PubMed ID: 15250019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.